Generation Bio

Generation Bio Operating Cash Flow

Delisted

The Operating Cash Flow of Generation Bio (GBIO) as of Nov 10, 2026 is -88.56 M USD. In the previous year, Operating Cash Flow was -52.75 M USD — a change of 67.91% (lower).

Operating Cash Flow

-88.56 MUSD

YoY

67.91%

Last updated:

Operating Cash Flow of Generation Bio is 2024 -88.56 M USD. Operating Cash Flow of Generation Bio was 2023 -52.75 M USD. It decreases by 67.91% lower compared to the previous year.

The Generation Bio Operating Cash Flow history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Operating Cash Flow
Date
Operating Cash Flow
Jan 1, 2018
-28.12 M USD
Jan 1, 2019
-40.35 M USD
Jan 1, 2020
-70.14 M USD
Jan 1, 2021
-91.82 M USD
Jan 1, 2022
-102.45 M USD
Jan 1, 2023
-52.75 M USD
Jan 1, 2024
-88.56 M USD
The Generation Bio Operating Cash Flow history
YEAROperating Cash FlowYoY
-88.56 MUSD+67.91%
-52.75 MUSD-48.52%
-102.45 MUSD+11.57%
-91.82 MUSD+30.91%
-70.14 MUSD+73.85%
-40.35 MUSD+43.48%
-28.12 MUSD—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Generation Bio Stock analysis

What does Generation Bio do? Generation Bio Co. is a genetic medicines company headquartered in Cambridge, Massachusetts, that focuses on creating a new class of gene therapy to provide durable and redosable treatment for patients suffering from both rare and prevalent diseases. The firm is developing a class of gene therapy utilizing its non-viral gene therapy platform to deliver genetic payloads to a range of tissues. The company’s non-viral gene therapy platform includes its DNA construct called closed-ended DNA (ceDNA), its cell-targeted lipid nanoparticle delivery system (ctLNP) and its established, scalable capsid-free manufacturing process. The firm is engineering its gene therapies to be redosable, which enable patient titration to reach the desired therapeutic expression and to maintain efficiency in a patient’s life. The firm is a preclinical stage company and have not identified a product candidate. Generation Bio is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Generation Bio stock

Operating Cash Flow of Generation Bio is -88.56 M USD in 2024.

Operating Cash Flow of Generation Bio changed from -52.75 M USD to -88.56 M USD, representing a 67.91% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Operating Cash Flow Generation Bio since 2006 – with annual values, charts, and detailed analysis.

Operating cash flow measures the cash generated from core business operations. It is a pure measure of a company's ability to generate cash.

Operating Cash Flow's USD is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track Operating Cash Flow's Generation Bio historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Cash Flow — Generation Bio

All Key Metrics — Generation Bio